Rafferty Asset Management
MRSN

Rafferty Asset Management’s Mersana Therapeutics MRSN Stock Holding History

Rafferty Asset Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-14,737
Closed -$1.65M – 1187
2024
Q1 		$1.65M Buy
+14,737
New +$1.47M 0.01% 734
2023
Q3 		– Sell
-13,466
Closed -$1.11M – 1093
2023
Q2 		$1.11M Sell
13,466
-5,962
-31% -$872K 0.01% 795
2023
Q1 		$2M Buy
19,428
+2,753
+17% +$386K 0.01% 613
2022
Q4 		$2.44M Buy
16,675
+8,124
+95% +$1.37M 0.02% 520
2022
Q3 		$1.45M Buy
+8,551
New +$1.39M 0.02% 584
2022
Q1 		– Sell
-11,152
Closed -$1.73M – 1290
2021
Q4 		$1.73M Buy
11,152
+4,671
+72% +$909K 0.01% 712
2021
Q3 		$1.53M Buy
6,481
+1,782
+38% +$521K 0.01% 705
2021
Q2 		$1.59M Sell
4,699
-2,705
-37% -$1.02M 0.01% 744
2021
Q1 		$3M Buy
7,404
+6,161
+496% +$2.99M 0.02% 497
2020
Q4 		$827K Sell
1,243
-1,855
-60% -$1.03M 0.01% 560
2020
Q3 		$1.44M Buy
3,098
+2,630
+562% +$1.33M 0.02% 507
2020
Q2 		$274K Buy
+468
New +$160K ﹤0.01% 852

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Rafferty Asset Management's MRSN Position: Q2 2024 in Review

Rafferty Asset Management sold out of Mersana Therapeutics (MRSN) in Q2 2024, closing a stake of 14,737 shares — an estimated $1.65M sold.

Rafferty Asset Management first reported a position in MRSN in Q2 2020 and held it in 12 quarters. The position peaked at $3M in Q1 2021. 120 funds tracked by Wall St. Rank hold MRSN as of Q2 2024.

  • Rafferty Asset Management reported no remaining Mersana Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Rafferty Asset Management sold 14,737 Mersana Therapeutics shares in Q2 2024, an estimated $1.65M.
  • Rafferty Asset Management first reported a position in Mersana Therapeutics in Q2 2020 and held it in 12 quarters.
  • Rafferty Asset Management's Mersana Therapeutics position peaked at $3M in Q1 2021.
  • 120 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2024.

Based on Rafferty Asset Management's 13F filing for Q2 2024, filed 13 Aug 2024.